COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 14th April 2020. As a result, our offices will now be closed till 14th April 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details. editor@innovativepublication.com, rakesh.its@gmail.com, Mob. 8826373757, 8826859373, 9910947804

Article view: 41

Article download: 33

IP Journal of Diagnostic Pathology and Oncology


Survival analysis of triple negative breast cancer patients treated with Anthracycline based chemotherapy: A Retrospective Study from Central part of India


Full Text PDF Share on Facebook Share on Twitter


Research Article

Author Details : Abhishek Shrivastava, Dheerendra Kumar Sachan*, Ruchita Sachan, Varsha Mandloi

Volume : 5, Issue : 1, Year : 2020

Article Page : 9-12


Suggest article by email

Abstract

Introduction: Triple negative breast cancer (TNBC) is diagnosed more frequently in younger and
premenopausal women. TNBC are biologically aggressive tumours, not benefited from hormonal or
targeted therapy although some reports suggest that they respond well to chemotherapy. The aim of our
study is was to assess the response of anthracyclines based adjuvant chemotherapy in triple negative breast
cancer.
Materials and Methods: This is was a retrospective study conducted on 100 post-operative patients,
histopathologically proven ductal Carcinoma Breast, from January 2016 to March 2017 presenting to
tertiary care centre. All patients were triple negative as assessed by immunohistochemistry and fluorescence
in situ hybridization technique. Patients were planned for six cycles of Anthracycine based combination
adjuvant chemotherapy. Data were analyzed by SPSS 20 and survival analysis was done.
Results: A total of 100 patients were included in this study. Out of these,18patients (18%) were defaulted
after chemotherapy, 29 patients (29%) were lost during subsequent follow ups and 49 patients (49%) had
disease free survival (DFS) and 4 patients (4%) survived with bone metastasis. The median survival was
18 months, disease free survival was 7.8 months and 3 year overall survival (OS) was 18.6 months.
Conclusions: TNBC represent a challenge for the patients and the clinician due to its poor prognosis and
fewer treatment options. The adjuvant Anthracycline -based combination chemotherapy predict improved
long term outcomes for TNBC.

Keywords: TNBC, Survival analysis, Anthracycline based chemotherapy

Doi : 10.18231/j.jdpo.2020.002

How to cite : Shrivastava A, Sachan D K, Sachan R , Mandloi V, Survival analysis of triple negative breast cancer patients treated with Anthracycline based chemotherapy: A Retrospective Study from Central part of India. IP J Diagn Pathol Oncol 2020;5(1):9-12

Copyright © 2020 by author(s) and IP J Diagn Pathol Oncol. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (creativecommons.org)